Kingdon Capital Management, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Kingdon Capital Management, L.L.C.
- $639 Million
- Q2 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 2,100,000 shares of SNDX stock, worth $32.4 Million. This represents 3.08% of its overall portfolio holdings.
Number of Shares
2,100,000
Previous 2,000,000
5.0%
Holding current value
$32.4 Million
Previous $24.6 Million
19.95%
% of portfolio
3.08%
Previous 2.81%
Shares
5 transactions
Others Institutions Holding SNDX
# of Institutions
247Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$132 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$122 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$89.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$77.7 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$62.8 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $873M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...